Join Defeat Duchenne Canada for an educational webinar featuring Dr. Jahannaz Dastgir, Executive Director of Clinical Development at REGENXBIO, as she shares the latest updates on RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy, and their Phase 1/2/3 AFFINITY DUCHENNE® trial.

This session will provide valuable insights into the science behind RGX-202, trial progress, and what this potential investigational treatment could mean for the Duchenne community. Whether you are a parent, caregiver, clinician, or advocate, this webinar is an opportunity to stay informed and ask questions directly to the team leading this important research.

What to expect:

• An overview of RGX-202 and how it is designed to work

• Updates on the AFFINITY DUCHENNE® clinical trial

• Insight into next steps and participation opportunities

• Live Q&A with Dr. Dastgir

This event is free and open to all. Advance registration is required.